Eli Lilly and Novo Nordisk have agreed to sell their weight loss drugs, Wegovy and Zepbound, through the new TrumpRx ...

Eli Lilly and Novo Nordisk May Soon Sell Weight Loss Drugs on the Planned TrumpRx. Could This Further Boost the Healthcare ...

After writing dozens of GLP-1 articles over the past year, one issue that consistently comes up is the affordability of ...

Trump announced popular weight loss treatments would be offered directly on a new “TrumpRx.gov” website at lower prices.

Even $149 a month, the advertised price for a starting dose of a still-in-development GLP-1 pill on TrumpRx, will be too big ...

In summary, under the Trump plan, the U.S. health system continues to fail Americans — by not viewing obesity as a disease, ...

TrumpRx will offer Novo Nordisk's Ozempic and Wegovy through TrumpRx for $350 and Eli Lilly and Company's Zepbound and orforglipron, if approved by the FDA, for $346.

Orforglipron is Lilly’s oral GLP-1 in phase 3 development as a treatment for diabetes and obesity. The FDA is expected to approve the drug in March 2026. Lilly’s November news release states that the ...

By moving early, Novo Nordisk has got in with its price cut ahead of Lilly, whose deal involved dual GLP-1/CIP agonist ...

Sen. Ruben Gallego (D-Ariz.) is asking for more information on Eli Lilly’s recently announced agreement with the Trump administration regarding the sale of its GLP-1 medication. In a letter ...

In a landmark deal announced this month, President Donald Trump negotiated dramatically lower costs for weight-loss drugs ...